These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24643716)

  • 1. Tirosine kinase inhibitors adverse events.
    Campiotti L; Maresca A; Guasti L; Grandi AM
    Oncologist; 2014 Mar; 19(3):306-7. PubMed ID: 24643716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In reply.
    Lenihan DJ; Kowey PR
    Oncologist; 2014 Mar; 19(3):307. PubMed ID: 24643717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.
    Lenihan DJ; Kowey PR
    Oncologist; 2013; 18(8):900-8. PubMed ID: 23918069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse kidney effects of epidermal growth factor receptor inhibitors.
    Izzedine H; Perazella MA
    Nephrol Dial Transplant; 2017 Jul; 32(7):1089-1097. PubMed ID: 28339780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.
    Li J; Wang M; Zhang B; Wu X; Lin TL; Liu XF; Zhou Y; Zhang XH; Xu H; Shen LJ; Zou J; Lu P; Zhang D; Gu WJ; Zhang MX; Pan J; Cao H;
    World J Gastroenterol; 2018 Dec; 24(46):5189-5202. PubMed ID: 30581268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma.
    Srinivas S; Stein D; Teltsch DY; Tao S; Cisar L; Ramaswamy K
    J Oncol Pharm Pract; 2018 Dec; 24(8):574-583. PubMed ID: 28732453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.
    Rimassa L; Danesi R; Pressiani T; Merle P
    Cancer Treat Rev; 2019 Jul; 77():20-28. PubMed ID: 31195212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of adverse effects/toxicity of ibrutinib.
    Paydas S
    Crit Rev Oncol Hematol; 2019 Apr; 136():56-63. PubMed ID: 30878129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of target small molecule tyrosine kinase inhibitors that need monitoring and clinical application of protocol for early detection of cancer therapeutics-related cardiac dysfunction using signal detection: An investigation of real world data.
    Mizuno T; Sakai T; Tanabe K; Kozaki K; Umemura T; Higashikawa M; Kimura T; Yamada T; Goto N; Ohtsu F
    J Oncol Pharm Pract; 2021 Jun; 27(4):804-814. PubMed ID: 32539664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.
    Resteghini C; Cavalieri S; Galbiati D; Granata R; Alfieri S; Bergamini C; Bossi P; Licitra L; Locati LD
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):349-361. PubMed ID: 28911730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
    Carneiro BA; Kaplan JB; Giles FJ
    Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Ibrutinib Toxicities: a Practical Guide.
    Lasica M; Tam CS
    Curr Hematol Malig Rep; 2020 Jun; 15(3):177-186. PubMed ID: 32415406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
    Srikanthan A; Ethier JL; Ocana A; Seruga B; Krzyzanowska MK; Amir E
    PLoS One; 2015; 10(3):e0122735. PubMed ID: 25815472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical review: kinase inhibitors: adverse effects related to the endocrine system.
    Lodish MB
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1333-42. PubMed ID: 23450053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of immune checkpoint inhibitor-related dermatologic adverse events.
    Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients.
    Totzeck M; Mincu RI; Mrotzek S; Schadendorf D; Rassaf T
    Eur J Prev Cardiol; 2018 Mar; 25(5):482-494. PubMed ID: 29376753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of immune checkpoint inhibitor-related rheumatic adverse events.
    Zhou J; Wang H; Guo X; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Zhang W; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):198-202. PubMed ID: 31762209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
    Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction.
    Duan L; Wang L; Wang H; Si X; Zhang L; Liu X; Li Y; Guo X; Zhou J; Zhu H; Zhang L
    Thorac Cancer; 2020 Apr; 11(4):1099-1104. PubMed ID: 32043816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.